Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Zachary Brennan

Senior Editor

Intarcia Therapeutics, once valued at more than $5 billion and attracting investors like the Bill & Melinda Gates Foundation, is now tussling with the FDA’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Intar­cia may fi­nal­ly get its post-CRL re­view, al­though FDA points to Covid and an­oth­er hear­ing as tak­ing pri­or­i­ty

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?